JP Morgan: "Overweight" rating on China Merchants Bank (03968) with a target price of HK$53.
China Merchants Bank announced its financial report for the last quarter, showing strong performance far exceeding expectations.
J.P. Morgan published a research report stating that China Merchants Bank (03968) has been given a "overweight" rating with a target price of HK$53.
The report mentioned that China Merchants Bank released its third-quarter performance report, which surpassed expectations with a strong performance. Operating profit increased by 8% year-on-year, reversing the 1% decline in the first three quarters of last year, exceeding J.P. Morgan's and market expectations by 5% and 8% respectively. Quarterly operating income also increased by 8% year-on-year, reaching 84.8 billion RMB, exceeding the bank's forecast by 4%. Net interest income was in line with expectations, while non-interest net income performed well and was the main driver of revenue growth. J.P. Morgan expects that the stock price of China Merchants Bank will positively respond.
J.P. Morgan believes that China Merchants Bank is the best-performing retail bank among Chinese banks. In the first half of last year, the retail deposit level per branch was significantly higher than other industry peers, and its deposit costs were also the lowest among joint-stock banks and urban commercial banks. It is expected to be an advantage in an environment where deposit interest rates are liberalized.
Related Articles

From Trillion-Dollar Computing Power to the "Next-Generation Drug King": Value Divergence and Capacity Fulfillment in NVIDIA's AI4S Ecosystem

How can medical AI move from "accurate diagnosis" to "practical application"? DIAGENS-B (02526) and Anzhen'er explore a new model of regional collaboration.

Guangzhou Automobile Group (02238) trading suspended from September 14 pending release of inside information.
From Trillion-Dollar Computing Power to the "Next-Generation Drug King": Value Divergence and Capacity Fulfillment in NVIDIA's AI4S Ecosystem

How can medical AI move from "accurate diagnosis" to "practical application"? DIAGENS-B (02526) and Anzhen'er explore a new model of regional collaboration.

Guangzhou Automobile Group (02238) trading suspended from September 14 pending release of inside information.

RECOMMEND





